Depot-medroxyprogesterone acetate does not reduce the prophylactic efficacy of emtricitabine and tenofovir disoproxil fumarate in macaques

Jessica Ann Radzio-Basu, Krisztina Hanley, James Mitchell, Shanon Ellis, Frank Deyounks, Leecresia Jenkins, Walid Heneine, J. Gerardo García-Lerma

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Concerns that the injectable contraceptive depotmedroxyprogesterone acetate (DMPA) may increase the risk of HIV acquisition in women led to questions on whether DMPA could reduce efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention. We used a macaque model to investigate the impact of prolonged DMPA exposure on PrEP with emtricitabine/tenofovir disoproxil fumarate. Twelve pigtail macaques treated with DMPA were exposed vaginally to simian HIV once a week for up to 5 months and received either placebo (n = 6) or emtricitabine/tenofovir disoproxil fumarate (n = 6). All control macaques were infected, whereas the PrEP-treated animals remained protected (P = 0.0007). This model suggests that women using DMPA will fully benefit from PrEP.

Original languageEnglish (US)
Pages (from-to)365-369
Number of pages5
JournalJournal of Acquired Immune Deficiency Syndromes
Volume67
Issue number4
DOIs
StatePublished - Jan 1 2014

Fingerprint

Tenofovir
Medroxyprogesterone Acetate
Macaca
Acetates
HIV
Macaca nemestrina
Contraceptive Agents
Placebos
Emtricitabine
Injections

All Science Journal Classification (ASJC) codes

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Radzio-Basu, Jessica Ann ; Hanley, Krisztina ; Mitchell, James ; Ellis, Shanon ; Deyounks, Frank ; Jenkins, Leecresia ; Heneine, Walid ; García-Lerma, J. Gerardo. / Depot-medroxyprogesterone acetate does not reduce the prophylactic efficacy of emtricitabine and tenofovir disoproxil fumarate in macaques. In: Journal of Acquired Immune Deficiency Syndromes. 2014 ; Vol. 67, No. 4. pp. 365-369.
@article{e5c13fa82bc64d22ad52080ef2e5d17c,
title = "Depot-medroxyprogesterone acetate does not reduce the prophylactic efficacy of emtricitabine and tenofovir disoproxil fumarate in macaques",
abstract = "Concerns that the injectable contraceptive depotmedroxyprogesterone acetate (DMPA) may increase the risk of HIV acquisition in women led to questions on whether DMPA could reduce efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention. We used a macaque model to investigate the impact of prolonged DMPA exposure on PrEP with emtricitabine/tenofovir disoproxil fumarate. Twelve pigtail macaques treated with DMPA were exposed vaginally to simian HIV once a week for up to 5 months and received either placebo (n = 6) or emtricitabine/tenofovir disoproxil fumarate (n = 6). All control macaques were infected, whereas the PrEP-treated animals remained protected (P = 0.0007). This model suggests that women using DMPA will fully benefit from PrEP.",
author = "Radzio-Basu, {Jessica Ann} and Krisztina Hanley and James Mitchell and Shanon Ellis and Frank Deyounks and Leecresia Jenkins and Walid Heneine and Garc{\'i}a-Lerma, {J. Gerardo}",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/QAI.0000000000000340",
language = "English (US)",
volume = "67",
pages = "365--369",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Depot-medroxyprogesterone acetate does not reduce the prophylactic efficacy of emtricitabine and tenofovir disoproxil fumarate in macaques. / Radzio-Basu, Jessica Ann; Hanley, Krisztina; Mitchell, James; Ellis, Shanon; Deyounks, Frank; Jenkins, Leecresia; Heneine, Walid; García-Lerma, J. Gerardo.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 67, No. 4, 01.01.2014, p. 365-369.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Depot-medroxyprogesterone acetate does not reduce the prophylactic efficacy of emtricitabine and tenofovir disoproxil fumarate in macaques

AU - Radzio-Basu, Jessica Ann

AU - Hanley, Krisztina

AU - Mitchell, James

AU - Ellis, Shanon

AU - Deyounks, Frank

AU - Jenkins, Leecresia

AU - Heneine, Walid

AU - García-Lerma, J. Gerardo

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Concerns that the injectable contraceptive depotmedroxyprogesterone acetate (DMPA) may increase the risk of HIV acquisition in women led to questions on whether DMPA could reduce efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention. We used a macaque model to investigate the impact of prolonged DMPA exposure on PrEP with emtricitabine/tenofovir disoproxil fumarate. Twelve pigtail macaques treated with DMPA were exposed vaginally to simian HIV once a week for up to 5 months and received either placebo (n = 6) or emtricitabine/tenofovir disoproxil fumarate (n = 6). All control macaques were infected, whereas the PrEP-treated animals remained protected (P = 0.0007). This model suggests that women using DMPA will fully benefit from PrEP.

AB - Concerns that the injectable contraceptive depotmedroxyprogesterone acetate (DMPA) may increase the risk of HIV acquisition in women led to questions on whether DMPA could reduce efficacy of pre-exposure prophylaxis (PrEP) for HIV prevention. We used a macaque model to investigate the impact of prolonged DMPA exposure on PrEP with emtricitabine/tenofovir disoproxil fumarate. Twelve pigtail macaques treated with DMPA were exposed vaginally to simian HIV once a week for up to 5 months and received either placebo (n = 6) or emtricitabine/tenofovir disoproxil fumarate (n = 6). All control macaques were infected, whereas the PrEP-treated animals remained protected (P = 0.0007). This model suggests that women using DMPA will fully benefit from PrEP.

UR - http://www.scopus.com/inward/record.url?scp=84919387017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919387017&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000000340

DO - 10.1097/QAI.0000000000000340

M3 - Article

C2 - 25202923

AN - SCOPUS:84919387017

VL - 67

SP - 365

EP - 369

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 4

ER -